What's going on with 23andMe stock?
In 2018, 23andMe secured a $300 million upfront equity investment from GlaxoSmithKline ( NYSE:GSK) to develop new therapeutics, with $127 million more in research revenue coming between then and mid-2023. Lastly, 23andMe is combining its genetic research and testing to curate a subscription service for its consumers.
Is 23andMe efficiently forecasting its sales?
However, its forecast for this year amounts to just $243.5 million in sales. 23andMe is, fortunately, improving its operating income less noncash items from a loss of $85 million in 2019 to a positive $7.5 million this year. It's clear that management sees the problem as well.
How accurate is the 23andMe test?
The 23andme testing service was founded to help patients personally manage and control their health. Ancestry estimate percentages are accurate down to the 0.1% So is it 23andme worth it?
How much will 23andMe be worth after the vgac deal?
Once VGAC's shareholders vote to consent to the deal, the shell company will be delisted and 23andMe will trade on the New York Stock Exchange (NYSE) under the ticker ME. Per the terms of the merger, it could get as much as $984 million in cash. That would leave it with an implied enterprise value of $3.5 billion.
See more
Is 23 and me a good stock to buy?
It depends on whether you look at where the company is today or where it's going tomorrow. 23andMe (ME 4.96%) investors have had a bumpy ride in the last 12 months. The company's shares are down by more than 67%, quarterly revenue growth has slumped into the single digits, and profitability remains far out of reach.
Why is 23andMe stock so low?
What happened. Shares of 23andMe (NASDAQ: ME) dropped 29.1% in November, according to data from S&P Global Market Intelligence. The DNA testing and therapeutics company reported a disappointing quarterly report and likely fell victim to the sell-off in high-growth names last month.
Is 23andMe on the stock market yet?
It's been far from a smooth ride since 23andMe's stock market debut. The Silicon Valley-based genetics testing firm went public in June via a merger with a special acquisition company led by U.K. billionaire Richard Branson in a deal that raised nearly $600 million and boosted 23andMe's value to $3.5 billion.
How do I invest in 23andMe stock?
How to buy shares in 23andMe HoldingCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Is 23andMe a profitable company?
In 2021, management predicts a total of around $247 million in revenue compared to 2020's sum of $305 million. And even in 2019's bumper crop year of sales, it wasn't anywhere near being profitable.
Who owns 23andMe?
Anne Wojcicki, the cofounder and CEO of 23andMe, owns 99.4 million shares of the merged company; with shares trading on the Nasdaq under the ticker “ME” at $13.40 as of 3:00pm EDT Thursday, her stake is worth approximately $1.3 billion.
What is a SPAC stock?
Special Purpose Acquisition Companies or SPACs are non-operating publicly-listed companies whose purpose is to identify and purchase a private company, allowing the acquisition target to have publicly listed stock. SPACs are also known as blank check companies.
When did 23&Me Go public?
June 17, 2021According to a 23andMe news release, “The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market (“NASDAQ”) beginning on June 17, 2021, under the new ticker symbol 'ME' for its Class A Common shares and 'MEUSW' for its public warrants.”
Does 23andMe pay dividends?
23andMe does not currently pay dividends.
Is me a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: ME) stock is to Buy ME stock. Out of 2 analysts, 0 (0%) are recommending ME as a Strong Buy, 1 (50%) are recommending ME as a Buy, 1 (50%) are recommending ME as a Hold, 0 (0%) are recommending ME as a Sell, and 0 (0%) are recommending ME as a Strong Sell.
Will me stock go up?
The 1 analysts offering 12-month price forecasts for 23andMe Holding Co. have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +146.05% increase from the last price of 2.85.
Who is the founder of 23andMe married to?
Sergey BrinAnne WojcickiEducationYale University (BS)Known forCo-founder and CEO of 23andMeSpouse(s)Sergey Brin ( m. 2007; div. 2015)Children24 more rows